Trial Profile
A Phase 2 Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Spartalizumab (Primary) ; Trametinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 01 Feb 2023 Primary endpoint has been met. (Overall Response Rate), as per Results published in the Nature Medicine
- 01 Feb 2023 Status has been changed to completed, as per Results published in the Nature Medicine
- 01 Feb 2023 Results published in the Nature Medicine